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Abstract 
Background: Retroperitoneal sarcomas (RPS) should be surgically managed in specialized sarcoma centers. However, 
it is not clearly demonstrated if clinical outcome is more influenced by Center Case Volume (CCV) or by Surgeon Case 
Volume (SCV). The aim of this study is to retrospectively explore the relationship between CCV and SCV and the qual-
ity of surgery in a wide region of Northern Italy.
Methods: We retrospectively collected data about patients M0 surgically treated for RPSs in 22 different hospitals 
from 2006 to 2011, dividing them in two hospital groups according to sarcoma clinical activity volume (HCV, high 
case volume or LCV, low case volume hospitals). The HCV group (> 100 sarcomas observed per year) included a 
Comprehensive Cancer Center (HVCCC) with a high sarcoma SCV (> 20 cases/year), and a Tertiary Academic Hospital 
(HVTCA) with multiple surgeon teams and a low sarcoma SCV (≤ 5 cases/year for each involved surgeon). All other 
hospitals were included in the LCV group (< 100 sarcomas observed per year).
Results: Data regarding 138 patients were collected. Patients coming from LCV hospitals (66) were excluded from 
the analysis as prognostic data were frequently not available. Among the 72 remaining cases of HCV hospitals 60% of 
cases had R0/R1 margins, with a more favorable distribution of R0/R1 versus R2 in HVCCC compared to HVTCA.
Conclusions: In HCV hospitals, sarcoma SCV may significantly influence RPS treatment quality. In low-volume centers 
surgical reports can often miss important prognostic issues and surgical quality is generally poor.
Keywords: Retroperitoneal sarcomas, Multidisciplinary management, Hospital case volume, Surgeon case volume, 
Quality of surgery, Retrospective analysis
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Background
Retroperitoneal sarcomas (RPS) account for 10–15% 
of soft tissue sarcomas (STS) with an expected 
annual incidence of nearly 1500 cases in Europe and 
an expected 5-year overall survival (OS) of 30–35% 
[1]. Histopathological analysis can reveal multiple 
histotypes with liposarcoma and  leiomyosarcoma as 
the most common [2].
The mainstay of treatment is surgical resection due to 
its survival advantage over nonsurgical treatments [3]. 
The intent of surgery is complete tumor resection with 
negative margins, which may require en bloc removal 
of adjacent involved organs or tissues. Of course, a 
wide margin per se may not be enough to guarantee an 
improved prognosis especially in specific histotypes 
(e.g. leiomyosarcoma) thus making it crucial to balance 
between wider excision and multimodal treatments [4]. 
Given the low incidence of RPS, individual hospitals and 
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surgeons generally observe very few cases; for this rea-
son available guidelines and consensus-papers state that, 
as a complex and rare disease, every case of RPS should 
be referred to a specialized sarcoma center and managed 
by a multidisciplinary team [5–7]. However, it is unclear 
what factor(s), for example, case volume, surgeon activ-
ity volume, hospital type, or the availability of adjuvant 
therapies, is/are the principal driver(s) of improved 
outcomes.
It is not clearly demonstrated if for STS, and specifically 
for RPS, clinical outcome is more influenced by center 
case volume (CCV) or by surgeon case volume (SCV). 
In the literature, the effect of surgeon versus hospital 
volume on outcomes after complex oncological surgery 
is poorly characterized [8]. Published retroperitoneal 
sarcoma series are mostly collected from high volume 
centers, in which the multidisciplinary aspect is most 
relevant rather than the surgeon’s caseload. The lack of 
surgeon-specific identifiers makes impossible to explore 
the interplay between hospital and surgeon volume and 
their impact on oncological outcomes. Therefore, it is 
unclear whether the principal determinant of oncological 
outcomes is high hospital case volume or high surgeon 
case volume. Providing care for RPS patients frequently 
requires a multidisciplinary team approach, and the team 
itself may be just as important than the surgeon in pro-
ducing favorable outcomes.
NICE guidelines state that a surgeon with specific 
expertise in these tumors, who is a core member of the 
multidisciplinary team (MDT), is needed within a refer-
ence center; they also consider the number of new cases 
per year as an important quality evaluation item for sar-
coma multidisciplinary teams. A sarcoma MDT should 
be expected to manage at least 100 new STS patients per 
year, and this caseload should be based either in a single 
hospital or in several geographically close and closely 
affiliated hospitals, which would constitute a sarcoma 
treatment network [9].
Due to the rarity of these diseases, it is difficult for a 
general surgeon to reach an adequate case volume. The 
only paper dealing with the problem of adequate surgical 
volumes in STS proposed a ≥  5 sarcoma surgeries/year 
cut off, after an analysis of 4205 STS cases registered in 
the Florida Cancer Data System (FCDS) in which medi-
cal facilities above the 67th percentile for volume were 
defined as high-volume centers [10].
Concerning the treatment of retroperitoneal sarcomas, 
the aim of this study is to retrospectively explore the 
relationship between the hospital or surgeon case vol-
ume and the quality of surgery in a region of Northern 
Italy.
Methods
We retrospectively collected data concerning two regions 
of northern Italy, Piedmont and Aosta Valley (with a total 
amount of 4.5 million of inhabitants), to identify RPS 
patients, without distant metastases at diagnosis, oper-
ated during the period from 2006 to 2011 in order to ana-
lyze care center characteristics (according to high or low 
CCV and SCV) and quality of surgical treatment. Data 
collection was authorized by a partnership between the 
Department « Rete Oncologica del Piemonte e della Valle 
d’Aosta  »  (Piedmont and Aosta Valley Oncologic Net-
work) and Italian Pathologist Association (SIAPEC) stip-
ulated in June 2012; all data were recorded anonymously 
respecting Italian privacy rules.
Data of histopathological reports from January 2006 to 
December 2011 were collected from local databases of 
22 different hospitals. According to the type of electronic 
database available in every single hospital, site-specific 
search strings were prepared using keywords able to 
describe the site and the morphology (i.e. “retroperito-
neum” and/or “sarcoma”) and SNOMED codes used for 
sarcomas morphology [11].
All extracted cases were screened by a skilled medi-
cal oncologist and collected in an encrypted database, 
which contained clinical and histopathological data, with 
particular attention to ESMO guidelines main prognos-
tic items such as tumor size, grading, surgical margins 
(according to the R0, 1 and 2 ranking), preoperative 
biopsy and tumor integrity.
In our study patients data retrieved from different hos-
pitals were split in two groups according to their yearly 
sarcoma caseload, adopting the 100 cases/year cut-off 
rule suggested by NICE [9] (Fig. 1).
In the “high volume” group two institutions 
were included:
Fig. 1 Series distribution according to activity volumes adopting the 
100 cases/year cut-off rule suggested by NICE [9]
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  • “Candiolo Cancer Center, a high volume Compre-
hensive Cancer Center (HVCCC) with nearly 150 
STS cases observed per year.
  • “Città della Salute e della Scienza” San Giovanni Bat-
tista hospital, a high volume Tertiary Care Academic 
hospital (HVTCA) with more than 100 STS cases 
observed per year.
In the “low volume” group all other hospitals were 
included (low volume secondary care hospitals, LVSCH).
In this series three different approaches to RPS are 
represented:
  • HVCCC, a high-volume cancer center with a sar-
coma-committed surgical team (high CCV and 
SCV > 20 surgeries per year) and a regular RPS-mul-
tidisciplinary board (RMB);
  • HVTCA, a high-volume tertiary care academic hos-
pital without a sarcoma-committed surgical team 
(high CCV and SCV  ≤  5 cases per year for each 
involved surgeon) and a formalized RMB;
  • LVSCH, a group of low volume hospitals (low CCV 
and SCV < 5 RPS surgeries per year) without a for-
malized RMB.
Missing clinical informations concerning the “high vol-
ume” group were sorted from the institutional internal 
electronic chart database of each institution.
Missing data about the patients in charge to LVSCH 
were not obtained, due to the absence of a reliable data-
base or, in case of an existing one, to access restrictions 
for external investigators.
Follow up was available only for the HV hospital 
patients; the median value was of 85  months (range 
72–100).
Statistical analysis
Data were analyzed with SAS system 9.2 software.
The crude and adjusted hazard ratios were calculated 
according to hospital, patient’s age, tumor size, grading, 
recurrent or primitive tumor. Two logistic regression 
models were adopted: for tumor integrity and for surgical 
margins (confidence limits 95%).
The Kaplan–Meier survival curve for primary/recur-
rent RPS was calculated on HV series. The Kaplan–Meier 
survival curve according to surgical margins was built 
with the high HCV hospitals data, and is based on 57 
patients.
Results
Data from 22 hospitals were available: 138 patients (55% 
males and 45% females) were identified with a diagnosis 
of RPS from 2006 to 2011.
According to care center volume 47 cases (34.1%) were 
treated in HVTCA, 25 (18.1%) in HVCCC: 66 cases 
(47.8%) were treated in LVSCH.
As regards this latter group of patients, the lack of 
essential information impaired any statistical analysis. In 
particular, no useful informations were available concern-
ing tumor diameter, preoperative biopsy, margins evalua-
tion and FNLCLCC grading. For this reason, data from 
this latter group was not considered in the subsequent 
analysis, which has been conducted only on HTVCA and 
HVCCC patients.
The main characteristics of this series are summarized 
in Table 1.
Seventeen different histotypes were observed. The 
most frequent was liposarcoma (55.5%), followed by leio-
myosarcoma (14%), sarcoma NOS (11%) and other his-
totypes. The difference between the two groups was not 
significant.
The tumor was primitive in 63.8% and recurrent 
in 36.2%: in HVCCC primaries were 56% and recur-
rences 44%; in HVTCA 68 and 32%. (Chi Squared test, 
P = 0.30).
According to FNCLCC grading, 14% of tumors were 
G1, 31% were G2 and 37.5% G3. In 17.5% of cases, this 
information was not recorded. The subdivision of grades 
G1/G2–3 in HVCCC and HVTCA was 31/52 and 53/30 
(Chi Squared test, P = 0.91), respectively.
Tumor diameter was smaller than 10  cm in 30.5% of 
cases (32% for HVTCA and 28% for HVCCC), greater 
than 10  cm in 69.5% (68% for HVTCA and 72% for 
HVCCC) (Chi Squared test, P = 0.2622).
A preoperative biopsy was performed in 63.8% of 
patients, of which 66.5% coming from HVTCA and 60% 
from HVCCC.
According to previous experiences [12, 13] surgical 
resections were classified as macroscopically complete (R0 
or R1) or incomplete (R2). 60% of RPS had a R0/R1 resec-
tion, 25% had R2 resection. In 15% of cases the status of 
surgical margins was not recorded. In HVCCC group the 
distribution R0/R1 versus R2 was 80 and 12%; in HVTCA, 
49 and 32% (Chi Squared test, P = 0.0133; Fig. 2).
Tumors were removed intact in 50% of cases. In 
HVCCC group the rate of fragmented/intact specimens 
was 24 and 76%, and in HVTCA, 63.8 and 36.2% (Chi 
Squared test, P = 0.01, Fig. 2), respectively.
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We compared HVTCA and HVCCC groups with 
the Chi squared test for grading, surgical margins, 
tumor size and intact specimen removal. In both 
logistic regression models concerning intact speci-
men and surgical margins (Table  2), only the “care 
center” item demonstrated a statistically significant 
correlation (i.e. HVCCC versus HVTCA) (P  =  0.03, 
adjusted effects).
5  years survival according to the quality of mar-
gins was 65% for R0–R1 and 31% for R2 patients (Chi 
Squared test, P  <  0.001) without differences between 
HVCCC and HVTCA cases (Chi Squared test, P = 0.06 
Fig. 3).
Table 1 patients from high volume centers (HCV) main characteristics
Statistically significant P values are in italic
HVTCA high volume Tertiary Care Academic Hospital, HVCCC high volume Comprehensive Cancer Center
Global HVC % HVTCA % HVCCC % HVTCA versus HVCCC
Age
 < 60 15 21.0 11 23.5 4 19.0 P = 0.81
 ≥ 60 57 79.0 36 76.5 21 81.0
Sex
 M 43 59.7 24 51.0 19 76.0 P = 0.62
 F 29 40.3 23 49.0 6 24.0
Primary/recurrent
 Primary 46 63.8 32 68.0 14 56.0 P = 0.30
 Recurrent 26 36.2 15 32.0 11 44.0
Diameter
 < 10 cm 22 30.5 15 32.0 7 28.0 P = 0.26
 ≥ 10 cm 50 69.5 32 68.0 18 72.0
Histotype
 Liposarcoma 40 55.5 24 51.0 16 64.0 P = ns
 Leiomyosarcoma 10 14.0 9 19.0 1 4.0
 Sarcoma NOS 8 11.0 1 2.0 7 28.0
 Others 14 19.5 13 28.0 1 4.0
Grading
 1 10 14.0 7 14.8 3 12.0 P = 0.9
 2 22 31.0 18 38.2 4 19.0
 3 27 37.5 14 30.0 13 52.0
 Unknown 13 17.5 8 17.0 5 17.0
Preoperative biopsy
 Yes 46 63.8 31 66.5 15 60.0 P = 0.45
 No 26 36.2 16 33.5 10 40.0
Margins
 R0 20 28.0 10 21.0 10 40.0 R0 + R1 versus R2 P = 0.013
 R1 23 32.0 13 28.0 10 40.0
 R2 18 25.0 15 32.0 3 12.0
 Unknown 11 15.0 9 19.0 2 8.0
Fragmentation
 Yes 36 50.0 30 63.8 6 24.0 P = 0.01
 No 36 50.0 17 36.2 19 76.0
Fig. 2 Analysis of margin involvement and specimen fragmenta-
tion according to the hospital of treatment (HVCCC versus HVTCA). P 
values are derived from Chi square test
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Discussion
The outcome of surgical treatment of many common 
tumors (as for example rectal cancer, breast cancer, 
lung cancer, prostate cancer, head and neck cancers and 
esophageal cancer) are clearly influenced by both center 
case volume (CCV) and surgeon case volume (SCV) [14, 
15].
In STS, several studies state that HCV hospital may 
assure higher survival rate [10, 16].
Some retrospective data show that the management of 
RPS in sarcoma-specialized centers is associated with a 
lower loco-regional relapse rate and a 5-year OS of nearly 
60–65% [17, 18] and that high-volume centers perform 
surgery more adherently to clinical STS guidelines than 
low-volume ones [19, 20].
In real life, up to 63% of STS in UK are referred to 
non-specialized centers [16]; up to 50% of non-oncology 
committed surgeons perform extremity soft tissue sar-
coma resections in California [21]. In a recent survey the 
German Interdisciplinary Sarcoma Group [22] analyzed 
university medical centers plus those ones treating more 
than 10 RPS per year in comparison to centers follow-
ing less than 10 RPS per year, finding relevant differences 
regarding tumor biopsy policy, resection strategies and 
multimodal therapies. Only 11 surgical departments on 
191 surveyed treated more than 10 RPS patients per year; 
Table 2 Logistic regression model about the factors potentially affecting the quality of surgical margins (R0/1 versus R2)
a HVCCC high volume Comprehensive Cancer Center, HVTCA high volume Tertiary Care Academic Hospital
Covariates Rough effects P IC95% Adjusted effects P IC95%
HVCCCa – – – – – –
HVTCA 5.262 0.0192 1.311–21.115 8.335 0.0306 1.220–57.242
Liposarcoma – – – – – –
Leiomyosarcoma 1.094 0.9059 0.248–4.829 1.193 0.8388 0.218–6.543
Others 1.176 0.8551 0.206–6.731 0.470 0.5620 0.037–6.034
Age 0.970 0.3390 0.912–1.032 0.973 0.4823 0.903–1.049
Primary – – – – – –
Recurrent 1.450 0.5490 0.430–4.889 3.252 0.1608 0.626–16.897
< 10 cm – – – – – –
> 10 cm 1.107 0.8830 0.285–4.297 0.808 0.8104 0.141–4.617
G1 – – – – – –
G2/G3 0.288 0.0797 0.071–1.159 0.365 0.3485 0.045–2.999
Unknown 3.718 0.2369 0.422–32.759 1.687 0.7363 0.080–35.384
R0/R1 HVCCC R0/R1 HVTCA R2 HVTCAR2 HVTCCC
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Fig. 3 Kaplan-Meyer curves according with the status of surgical margins (R0/R1 versus R2) patients from HVCCC versus patients from HVTCA
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in only 19 hospitals a multidisciplinary sarcoma board 
was active and in 54% of the departments pretreatment 
tumor biopsy was a standard procedure. These results 
suggest the need for dedicated RPS education programs 
and centralized registration for RPS treatment.
Berger et al. [23] identified 2762 patients from the US 
National Cancer Database treated for retroperitoneal 
sarcoma. The majority (59.4%, n  =  1642) underwent 
resection at an academic cancer center. Resection for 
retroperitoneal sarcoma performed at academic cancer 
center was an independent predictor of margin-negative 
resection but was not a statistically significant risk factor 
for survival, suggesting that site of care may contribute to 
the quality of retroperitoneal sarcoma surgery.
The management of soft tissue sarcomas requires inte-
grated care at a referral center, as suggested by existing 
guidelines and consensus statements. Diagnosis of the 
primary lesion, distant metastasis, or subsequent local 
recurrence require the use of advanced imaging as well 
as the expertise of appropriately trained teams. Experts 
involved in soft tissue sarcoma care suggest treatment 
with respect to using, dosing, and timing of radiation and 
chemotherapy tailored for every individual patient [5, 
24].
Surgery of RPS, especially for wide re-excision after 
unplanned primary excision of a mass, requires specific 
multidisciplinary teamwork [25, 26]. There are data con-
cerning RPS which show that patients treated in sarcoma 
reference centers can achieve better oncological out-
comes [17, 18].
In this study, we collected data concerning the treat-
ment of RPS from 22 hospitals, of which 20 (90%) treated 
less than 5 cases per year; the low quality of retrieved 
information from this low volume activity hospitals 
(LVSCH), mirrors the incidental character of this type of 
surgery.
We  considered margins as macroscopically negative 
(R0/R1) or macroscopically positive (R2), as available lit-
erature shows that this margin classification has a defi-
nite prognostic value without great differences between 
R0 and R1 in the retrospective setting; is  often difficult 
to correctly assess microscopic margins in big retroperi-
toneal masses in absence of a real compartment or of the 
possibility of a wide excision [6, 12, 13, 27–30]. The mul-
tivariate analysis confirmed that, within high CCV cent-
ers, the one with a dedicated surgical team and a RMB 
(HVCCC) had a better quality of macroscopic margins 
and a higher rate of intact tumor resection. Keung et al. 
[31] highlights the importance of maintaining tumor 
specimen integrity during surgery because tumor frag-
mentation is independently associated with worse PFS 
and OS. Bonvalot and colleagues [32] similarly reported 
that tumor rupture was associated with worse OS. 
Maintaining tumor specimen integrity is often a daunt-
ing challenge given the large size, location, and adjacent 
organ involvement of many of these tumors, and there-
fore, tumor integrity can be considered a proxy of surgi-
cal quality.
It is expected that outcomes directly under the sur-
geon’s control, that is, the completeness of resection, 
are more strongly associated with surgeon volume, a 
marker of surgical expertise, rather than by hospital vol-
ume, which is a somewhat imprecise marker of surgeon 
experience as well as hospital structure and process 
characteristics.
Important limitations of this study are its retrospec-
tive nature, based on histopathological reports, the omis-
sion of non-surgically treated patients, the retrieval of 
missing data from different databases and the absence of 
clinical history and follow-up information, particularly 
about RFS, in patients treated in LVSCH.
Conclusion
Outside reference or tertiary care centers, the quality of 
RPS management may be lower because the relevance of 
both tumor integrity and surgical margin quality are not 
completely understood and therefore, documented.
In light of the persistent association between improved 
surgical oncology outcomes and high-volume  activ-
ity, the centralization of high-risk cancer surgery has 
been proposed [26–28]. A volume-outcome relationship 
exists for RPS so, centralization may improve outcomes 
for RPS keeping in mind that surgical experience plays 
a larger role for these outcomes  than structural/process 
characteristics.
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